

Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age

Wendy W. Pang^{a,1}, Elizabeth A. Price^b, Debashis Sahoo^a, Isabel Beerman^c, William J. Maloney^d, Derrick J. Rossi^c, Stanley L. Schrier^b, and Irving L. Weissman^{a,1}

^aInstitute for Stem Cell Biology and Regenerative Medicine, Ludwig Center for Stem Cell Research, and Department of Pathology, ^bDepartment of Internal Medicine, Division of Hematology, and ^dDepartment of Orthopaedic Surgery, Stanford University, Stanford, CA 94305; and ^cImmune Disease Institute, Harvard Medical School, Boston, MA 02115

Contributed by Irving L. Weissman, October 20, 2011 (sent for review June 14, 2011)

In the human hematopoietic system, aging is associated with decreased bone marrow cellularity, decreased adaptive immune system function, and increased incidence of anemia and other hematological disorders and malignancies. Recent studies in mice suggest that changes within the hematopoietic stem cell (HSC) population during aging contribute significantly to the manifestation of these age-associated hematopoietic pathologies. Though the mouse HSC population has been shown to change both quantitatively and functionally with age, changes in the human HSC and progenitor cell populations during aging have been incompletely characterized. To elucidate the properties of an aged human hematopoietic system that may predispose to age-associated hematopoietic dysfunction, we evaluated immunophenotypic HSC and other hematopoietic progenitor populations from healthy, hematologically normal young and elderly human bone marrow samples. We found that aged immunophenotypic human HSC increase in frequency, are less quiescent, and exhibit myeloid-biased differentiation potential compared with young HSC. Gene expression profiling revealed that aged immunophenotypic human HSC transcriptionally up-regulate genes associated with cell cycle, myeloid lineage specification, and myeloid malignancies. These age-associated alterations in the frequency, developmental potential, and gene expression profile of human HSC are similar to those changes observed in mouse HSC, suggesting that hematopoietic aging is an evolutionarily conserved process.

lineage potential | hematopoiesis | microarray | leukemia

Hematopoiesis is initiated by hematopoietic stem cells (HSC) that can self-renew and progressively differentiate into a hierarchy of committed progenitors that ultimately give rise to mature blood cells (1). Though the mechanisms of aging in the hematopoietic system are comprised of a combination of cell-intrinsic and -extrinsic causes that ultimately alter the generation and function of mature blood lineages, there is increasing evidence that implicates alterations within the HSC population as one of the mechanisms behind hematopoietic aging. We and others have found that as mice age, their HSC numbers increase, but competitive repopulation ability is reduced, suggesting a decrease in mouse HSC function with age (2–7). Additionally, elderly mouse HSC exhibit a marked decrease in lymphopoiesis and increase in myelopoiesis (2, 6). In the mouse, we and others have identified distinct clonal subtypes of HSC that differentially respond to external cytokine stimuli and exhibit lineage bias upon transfer to irradiated hosts (8–13). The majority of HSC from elderly mice are myeloid biased, whereas most HSC from young mice are balanced in lymphopoiesis and myelopoiesis (8–13).

In humans, age-associated hematopoietic changes include decreased bone marrow cellularity (14), declines in lymphopoiesis (7, 15, 16), red cell abnormalities such as anemia (17), and increases in the incidence of myelodysplastic syndromes, myeloproliferative disorders, and myeloid malignancies (18). In human bone marrow, the HSC population is highly enriched within the Lin[−]CD34⁺CD38[−]CD90⁺CD45RA[−] population (19–24). Previous studies addressing the age-associated changes in human HSC have relied on indirect evaluations of stem and progenitor populations and

have therefore been less quantitative than studies of mouse HSC aging. The proliferative capacity of human HSC appears to decline from fetal liver, to cord blood, to adult bone marrow (25), and some indirect evidence suggests reductions in stem cell reserves with age (26, 27), particularly in the context of anemia (28). Clinically, in the setting of bone marrow transplantation, increasing donor age correlates with increasing transplant-related mortality (29). Few studies have evaluated the frequency of bone marrow progenitor populations directly: one study found that the number of CD34⁺ bone marrow cells decreases with age (30), whereas another study found that the frequency of CD34⁺CD38[−] bone marrow cells increases with age (31). However, CD34⁺ and CD34⁺CD38[−] bone marrow populations are both heterogeneous, only a small fraction of which are HSC.

Therefore, to more precisely identify changes within the stem cell compartments that contribute to human hematopoietic aging, we evaluated the putative human HSC compartment (immunophenotypically defined as Lin[−]CD34⁺CD38[−]CD90⁺CD45RA[−]) from healthy, young (20–35 y of age) human bone marrow samples (hereafter referred to as young HSC) and healthy elderly (65+ y of age) human bone marrow samples (hereafter referred to as elderly HSC). We characterized, by flow cytometry, the frequency, distribution, and cell-cycle profile of immunophenotypic HSC and other hematopoietic progenitor populations, and we found that aged immunophenotypic human HSC are increased in frequency and are less quiescent than young HSC. We sorted immunophenotypic human HSC from young and elderly bone marrow samples and tested their ability to proliferate and differentiate in vitro and in vivo. Both young and elderly immunophenotypic human HSC were able to generate lymphoid and myeloid progeny in culture, but elderly HSC exhibited significantly myeloid-biased differentiation potential compared with young HSC under equal conditions. Elderly immunophenotypic human HSC xenotransplanted into immunodeficient mice did not engraft or generate lymphoid progeny as efficiently as young human HSC. We also performed gene expression profiling of sorted young and elderly immunophenotypic human HSC. Our results suggest that a number of mechanisms behind the phenotype of hematopoietic aging are transcriptionally regulated at the level of diverse subsets of HSC.

Author contributions: W.W.P., E.A.P., D.J.R., S.L.S., and I.L.W. designed research; W.W.P., I.B., and D.J.R. performed research; W.J.M. contributed new reagents/analytic tools; W.W.P., E.A.P., D.S., S.L.S., and I.L.W. analyzed data; and W.W.P., S.L.S., and I.L.W. wrote the paper.

Conflict of interest statement: W.J.M. is on the board of and owns stock and options in Stemmedica Cell Technologies, Inc. I.L.W. is on the board of StemCells, Inc., and owns stock in Amgen, Inc.

Freely available online through the PNAS open access option.

Data deposition: The data reported in this paper have been deposited in the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE32719).

¹To whom correspondence may be addressed. E-mail: wendy.pang@stanford.edu or irv@stanford.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1116110108/-DCSupplemental.

Results

To directly characterize human HSC during aging, we first quantified by flow cytometry the frequency of immunophenotypic human HSC ($\text{Lin}^- \text{CD34}^+ \text{CD38}^- \text{CD90}^+ \text{CD45RA}^-$) in hematologically normal young and elderly bone marrow samples (Fig. 1A). We found that elderly bone marrow contain increased frequency of HSC within the CD34^+ population (Fig. 1B) as well as within the bone marrow mononuclear fraction (SI Appendix, Fig. S1), consistent with a recent finding in a small number of samples showing an age-associated increase in frequency of HSC (32). Quantification of the exact number of HSC was not possible because of the inherent variability in the technique of human bone marrow aspiration. We also observed, on average, an age-associated increase, albeit not statistically significant, in the frequency of multipotent progenitors (MPP; $\text{Lin}^- \text{CD34}^+ \text{CD38}^- \text{CD90}^- \text{CD45RA}^-$) (33) (SI Appendix, Fig. S2). We further investigated the age-associated expansion of human HSC by evaluating the cell-cycle status of young and elderly HSC using RNA (Pyronein Y) and DNA (Hoechst 33342) dyes (Fig. 1C and SI Appendix, Fig. S3). We found that a greater percentage of young HSC are Pyronin Y low, and likely in the quiescent G_0 phase of the cell cycle, compared with elderly HSC, of which there is a greater percentage that are Pyronin Y high, and likely in nonquiescent G_1 , S, or G_2 phases (Fig. 1C and SI Appendix, Fig. S3A and B).




Fig 1. Increased frequency of HSC in normal elderly bone marrow compared to young. (A) Gating strategy and flow cytometric profile of HSC (Lin^- , CD34^+ , CD38^- , CD90^+ , CD45RA^-) in representative hematopoietically normal young (Left) and elderly (Right) bone marrow samples. The left panels for each sample are gated on lineage negative (Lin^-) live cells, and the right panels are gated on $\text{Lin}^- \text{CD34}^+ \text{CD38}^-$ live cells. (B) Summary of HSC as frequency of total $\text{Lin}^- \text{CD34}^+$ population from multiple young ($n = 13$) and elderly ($n = 11$) bone marrow samples. * $P < 10^{-7}$. (C) Summary of quiescent G_0 (Hoechst 33342^{low}, Pyronin Y^{low}, correlating with 2N DNA and low levels of RNA) and non- G_0 (Pyronin Y^{high}, correlating with 2N to 4N DNA and higher levels of RNA) HSC frequency out of total HSC from multiple young ($n = 13$) and elderly ($n = 8$). # $P < 0.013$. Error bars represent standard deviation.

Because HSC differentiate into mature blood cells via a succession of committed progenitors, we next examined these populations in young and elderly bone marrow samples to determine whether age-associated increases in human HSC frequency corresponded to changes in frequency of human myeloid and lymphoid progenitors. We did not detect any differences in the frequency of the immunophenotypic common myeloid progenitors (CMP; $\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD123}^+ \text{CD45RA}^-$), granulocyte-macrophage progenitors (GMP; $\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD123}^+ \text{CD45RA}^+$), and megakaryocyte-erythrocyte progenitors (MEP; $\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD123}^- \text{CD45RA}^-$) (34) from young and elderly bone marrow (SI Appendix, Fig. S4A–C). However, elderly bone marrow did exhibit a relative decrease in the frequency of common lymphoid progenitors (CLP; $\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD127}^+$; Fig. 2 and SI Appendix, Fig. S5). Therefore, whereas the myeloid progenitor populations appear to be maintained with age, lymphoid progenitors decline.

To determine the changes in the developmental potential of aged human HSC, we analyzed the ability of young and elderly HSC to generate myeloid and lymphoid progeny in vitro, and engraft and differentiate in vivo. We used FACS to isolate young and elderly immunophenotypic human HSC. FACS-purified HSC were cocultured with AC6.2.1 cells, which can act as a surrogate for normal bone marrow stroma in supporting both myeloid and B-lymphoid differentiation of human HSC (24). We determined by flow cytometry the percentage of B cells (CD19^+) and myeloid cells (CD33^+ and/or CD13^+) generated by young and elderly human HSC (Fig. 3A). Young HSC, compared with elderly HSC, cultured for 14 d on AC6.2.1 cells yielded greater numbers, albeit not statistically significant, of human CD45^+ cells per HSC, suggesting greater plating efficiency (SI Appendix, Fig. S6A). Experiments using single HSC from either young or elderly bone marrow samples plated on AC6.2.1 did not yield quantifiable colonies at any appreciable frequency. Notably, we found that elderly HSC exhibit significantly diminished capacity to give rise to lymphoid B lineage cells, resulting in an increased proportion of myeloid cells being generated per HSC cultured on AC6.2.1, and an increased myeloid-to-lymphoid ratio (Fig. 3B). The decreased efficiency in the generation of lymphoid B lineage cells by elderly HSC may be a mechanism behind the




Fig 2. Decreased frequency of CLP in normal elderly bone marrow compared to young. (A) Gating strategy and flow cytometric profile of CLP (Lin^- , CD34^+ , CD127^+) in representative hematopoietically normal young (Left) and elderly (Right) bone marrow samples. The left panels for each sample are gated on lineage negative (Lin^-) live cells, and the right panels are gated on $\text{Lin}^- \text{CD34}^+$ live cells. (B) Summary of CLP as frequency of total $\text{Lin}^- \text{CD34}^+$ population from multiple normal young ($n = 10$) and elderly ($n = 7$) bone marrow samples. * $P < 2.0 \times 10^{-4}$.




Fig 4. Gene expression profiling of HSC from normal elderly and young bone marrow reveals transcriptional differences reflecting myeloid lineage-bias of elderly HSC. (A) Validation of microarray data by quantitative RT-PCR: average fold-change in the expression of selected genes as determined by microarray analysis (14 young and 8 elderly HSC samples) and quantitative RT-PCR (4 young and 4 elderly HSC samples; independent of samples analyzed by microarrays). Error bars represent standard deviation. Heat maps reflecting expression levels of (B) myeloid-specific and (C) lymphoid-specific age-regulated genes that are significantly differentially expressed between young and elderly HSC.

To identify changes in gene expression that may underlie the differences in frequency and developmental potential of young and elderly HSC, we used FACS to sort HSC from 14 young and eight elderly bone marrow samples for transcriptional profiling (>95% purity; *SI Appendix, Fig. S8*). We also obtained gene expression data for five midage (42–61 y of age) bone marrow samples. Using the significance analysis of microarray (SAM) algorithm (35), we identified 285 age-regulated genes in human HSC [false discovery rate (FDR) < 30%; *SI Appendix, Table S1*]. We confirmed the changes in expression of a subset of genes in sorted HSC from four young and four elderly independent samples using quantitative RT-PCR (Fig. 4A). Using Ingenuity Pathways Analysis (IPA) software, we found that this set of age-regulated genes significantly enriched for transcriptional networks and biological functions associated with cell-cycle, cell growth and proliferation, and hematopoietic development (*SI Appendix, Fig. S9 A–C*). We also found that elderly HSC up-regulate genes associated with signaling pathways, including ERK/MAPK and GM-CSF signaling, that are involved in the expansion and proliferation of hematopoietic stem and progenitor compartments (*SI Appendix, Fig. S9D*). Interestingly, biological functions and pathways associated with DNA repair and cell death are concurrently enriched (*SI Appendix, Fig. S9C*). Additionally, we found elderly HSC up-regulate several genes that have been implicated in human hematopoietic myeloid malignancies, including *Aurka*, *Fos*, *Hoxa9*, *Myc*, and *Trim13* (Fig. 4A and *SI Appendix, Table S2*). In contrast, young HSC express approximately twofold-higher levels of *Maff* (Fig. 4A and *SI Appendix, Table S2*), which is involved primarily in

translocations found in lymphoid leukemias more commonly seen in young patients. We also found, using IPA, that the age-regulated genes in HSC are significantly enriched for those that are involved in acute myeloid leukemia signaling (*SI Appendix, Fig. S9D*). In addition, we found that elderly HSC primarily up-regulate genes that specify myeloerythroid fate and function (Fig. 4B), and down-regulate genes associated with lymphopoiesis (Fig. 4C). These findings that the age-associated increased expression of myeloid-specification gene SELP and decreased expression of lymphoid-specification genes FLT3 and SOX4 in human HSC have also been observed in mouse HSC (2, 6, 36). The increase in transcription of myeloid lineage-specific genes in the elderly human HSC population correlates with our in vitro and in vivo results, suggesting that the lineage biases of aged immunophenotypic human HSC is in part transcriptionally defined.

Discussion

In this study, we have characterized the age-associated effects on human hematopoiesis at the level of the stem cell. In aged individuals, we have found that immunophenotypic human HSC, similar to mouse HSC, are increased in frequency. Because the process of bone marrow aspiration often allows for the inclusion of a small amount of peripheral blood in the acquired sample, and because the CD34⁺ population is found primarily in the bone marrow, we calculated the frequency of immunophenotypic human HSC, as a percentage of CD34⁺ cells, as the best proxy for the frequency of HSC in bone marrow. The increased variability in the frequency of immunophenotypic human HSC as a percentage of total bone marrow mononuclear cells is potentially due in part to differing amounts of peripheral blood cells within the acquired sample.

In addition, we have found that elderly immunophenotypic human HSC have poorer engraftment efficiency and are relatively more myeloid-biased than young HSC. The relative decrease in frequency of CLP in human bone marrow combined with the relative loss of B-cell potential and corresponding increase of myeloid potential of immunophenotypic HSC both in vitro and in vivo suggest that lineage bias of the HSC population changes with age. We were unable to measure significant differences in other lineages due to low chimerism; more robust in vitro and in vivo models for quantitative assessment of T-cell, erythroid, and megakaryocytic potentials of human HSCs will be needed to more thoroughly assess the lineage potential of human HSCs and confirm our hypothesis. Efficient functional assays of the engraftment and lineage potential of single human HSC would be the most ideal method to characterize aging human HSC, because the immunophenotypic human HSC population we have analyzed is likely heterogeneous, containing distinct subsets of HSC and potentially non-HSCs. Nevertheless, by examining a highly purified population that is significantly enriched for bone marrow-derived human HSC, we have begun to identify subtle but important age-associated properties of the HSC population, in terms of its frequency and developmental potential, which would have been missed if one looked at more heterogeneous hematopoietic progenitor pools.

Our data indicate that human hematopoietic aging, similar to mouse hematopoietic aging, is associated with changes in human HSC gene expression that reflect the quantitative and functional alterations seen in elderly HSC. The increase in elderly HSC frequency may be partly due to increased frequency of HSC in active cell-cycle phases. Elderly HSC up-regulate genes associated with cell-cycle, cell growth and proliferation, and hematopoietic development, corresponding well with the increased proportion of elderly HSC that we observed to likely be in more active cell-cycle phases. However, this increase in HSC frequency does not necessarily translate into improved HSC function, supported by our finding that elderly HSC do not have as high engraftment efficiency in our xenotransplantation model.

We and others have proposed that stem cells, due to their inherent self-renewing potential and longevity, are ideal reservoirs for DNA damage over the life of the organism, and can therefore accumulate the multiple genetic/epigenetic events required for a normal cell to become a cancer cell (37–40). Our gene expression

data shows that elderly HSC up-regulate genes associated with DNA repair and cell death, possibly indicating that elderly HSC have activated cell-cycle checkpoints in response to DNA damage. Even though more elderly HSC may be in the process of proliferating, we speculate that they may also be arrested at cell-cycle checkpoints, perhaps due to the presence of DNA damage, for which there is evidence in elderly mouse HSC (40, 41). This, in turn, may lead to increased recruitment of quiescent HSC into the cell cycle to maintain adequate levels of functional HSC at a given time.

In this study, we also showed that the decline in lymphopoiesis with age can be traced to the behavior of the stem cell, and the transcriptional up-regulation of genes that specify myeloid-lineage differentiation likely underlies the myeloid skewing observed in elderly HSC. This change in developmental potential observed within the HSC population during aging could be due to (i) all HSC changing from balanced myeloid-lymphoid potential to myeloid-biased with age or (ii) intrinsically myeloid-biased HSC outcompeting balanced-potential HSC during aging. In mice, small numbers of myeloid-biased HSC can be found among balanced-potential HSC in young 2-mo-old mice (8, 11, 12), suggesting that the young mouse HSC pool may contain **lineage-biased clones** that compete for niches and expansion signals. The young human HSC population may similarly contain clones of lineage-biased cells, the selection of which, during aging, results in the predominance of myeloid-biased HSC in the elderly. This myeloid-biased skewing of elderly HSC lineage potential that we have observed may be one mechanism behind the increased frequency of myeloid disorders and malignancies in elderly people. Another factor that may contribute to the increased incidence of myeloid malignancies with age is that elderly human HSC up-regulate genes implicated in myeloid malignancies, such as *Aurka*, *Fos*, *Hoxa9*, *Myc*, and *Trim13*. Although these genes likely play roles in the normal maintenance and functions of HSC, we speculate that the increased transcription of these genes may potentially facilitate translocations to these loci and thereby malignant transformation in elderly bone marrow. HSC in elderly bone marrow, having accumulated a lifetime of genomic insults and being transcriptionally as well as functionally myeloid biased, may also be more likely to contribute to the development myeloid, as opposed to lymphoid, diseases.

Changes within the human HSC population during aging could also be influenced by alterations in the interactions between HSC and their aging niches. In the mouse, there is evidence to suggest that the young and elderly mouse HSC populations respond differently to cytokines such as IL-7 and TGF- β (9, 12). In young and elderly human HSC, we observed differential expression of cytokine receptors and pathways, including enrichment of the ERK/MAPK signaling and GM-CSF signaling pathways in elderly HSC, which may be physiological responses by different subtypes of lineage-biased human HSC to the aging hematopoietic environment. In particular, the increase in elderly human HSC frequency and their myeloid bias may reflect the hematopoietic system's attempt to maintain homeostasis, ensuring adequate functional mature progeny. We speculate that the inability of elderly human HSC to maintain homeostasis contributes to age-associated cytopenias, including anemias and dysplasias.

Notably, the results from our functional analysis and gene expression profiling of young and elderly human HSC significantly parallel the data we and others have generated on young and elderly mouse HSC (2, 6, 36). Both aged human and mouse HSC are increased in frequency, and they are transcriptionally and functionally myeloid-biased in their differentiation potential. Not surprisingly, the set of differentially expressed genes between young and elderly human HSC shares overlap with the set of differentially expressed genes between young and elderly mouse HSC. These similarities strongly suggest that the biological processes that cause the hematopoietic aging phenotype are similar between human and mouse, and that mouse hematopoietic aging is a reasonable model of human hematopoietic aging.

Our data directly implicate the human HSC and their age-associated alterations in the frequency, function, and gene ex-

pression as vital contributors to the aging in the human **hematopoietic** system. Further studies will address the pathways involved in the aging of the healthy human HSC population and also characterize HSC from age-associated hematopoietic diseases to better understand the processes involved in changing healthy elderly HSC into diseased elderly HSC.

Methods

Human Samples. Normal young human bone marrow mononuclear cells were purchased from AllCells, Inc. Normal young and elderly human bone marrow samples were obtained from hematologically normal donors at the Stanford Medical Center with informed consent, according to an institutional review board (IRB)-approved protocol (Stanford IRB nos. 5112 and 10831). We analyzed a total of 15 elderly (ages 65–85), 28 young (ages 20–31), and 5 midage (ages 42–61) normal bone marrow samples. Peripheral blood complete blood count values, from samples for which data are available, can be found in *SI Appendix, Table S3*. Mononuclear cells from bone marrow samples were prepared using Ficoll-Paque PLUS (GE Healthcare) and either analyzed/sorted fresh or cryopreserved in 90% FBS, 10% DMSO in liquid nitrogen. There is inherent variability in the technique of human bone marrow aspiration, during which peripheral blood may be aspirated along with bone marrow; therefore, the mononuclear cell fraction obtained from each aspiration may contain a small but unpredictable percentage of peripheral blood mononuclear cells in addition to bone marrow mononuclear cells. Estimates of bone marrow cellularity were determined by examination of bone marrow core biopsies. Human CD34-positive cells were enriched using magnetic beads (Miltenyi Biotec; Stemcell Technologies).

Flow Cytometry Analysis and Cell Sorting. The following panel of antibodies (Caltag/Invitrogen and BD Biosciences) was used for analysis and sorting of human hematopoietic stem and progenitor populations: PE-Cy5-conjugated anti-human lineage markers (anti-CD2, RPA-2.10; anti-CD3, S4.1; anti-CD4, S3.5; anti-CD7, CD7-6B7; anti-CD8, 3B5; anti-CD10, 5-1B4; anti-CD11b, ICRF44; anti-CD14, TU.K.4; anti-CD19, SJ25-C1; anti-CD20, 13.6E12; anti-CD56, B159; anti-GPA, GA-R2), PB-conjugated anti-CD45RA, MEM56; PE-Cy7-conjugated anti-CD38, HIT2; FITC-conjugated or Alexa Fluor 700-conjugated anti-CD90 (Thy-1), 5E10; PE-conjugated or FITC-conjugated anti-CD123; PE-conjugated anti-CD127, hIL-7R-M21.

The following panel of antibodies was used for analysis of differentiated human hematopoietic populations and human engraftment/chimerism: PB-conjugated CD45, HI30; APC-conjugated anti-CD34, 8G12; Alexa Fluor 750-conjugated CD3, S4.1; Alexa Fluor 700-conjugated CD19, SJ25-C1; PE-conjugated CD13, TK1; PE-conjugated CD33, P67.6; PE-Cy5-conjugated GPA, GA-R2; FITC-conjugated CD41a, HIP8. The following panel of antibodies (eBiosciences) was used to identify mouse leukocytes and red blood cells, respectively: Alexa Fluor 488- or PE-Cy7-conjugated CD45.1, A20.1.7; PE-Cy5- or PE-Cy7-conjugated Ter119. Single-cell suspensions were prepared using standard methods from bone marrow of transplanted mice. Red blood cells were lysed using ACK buffer.

For analyses and sorting, except otherwise noted below, cells were stained with the appropriate antibody combinations for 30–60 min on ice, and dead cells were excluded by propidium iodide staining. Gating strategy used to separate CD90⁺ from CD90[−], CD45RA⁺ from CD45RA[−], CD123⁺ from CD123[−], and CD127⁺ from CD127[−] populations was fluorescence minus one.

For analysis of the HSC cell cycle, cells were resuspended at a concentration of 10⁶ cells/mL of HBSS medium (10% FCS, 20 mM Hepes, 1 g/L glucose, and 50 μ g/mL verapamil) and incubated for 30 min at 37 °C with 20 μ g/mL Hoechst 33342 (Invitrogen); 1 μ g/mL Pyronin Y (Sigma-Aldrich) was added and cells were incubated for another 10 min at 37 °C, stained with the appropriate antibody combination for identification of HSC for 30 min on ice, washed, and analyzed. Gating strategy used to identify quiescent G₀ (Hoechst 33342^{low}, Pyronin Y^{low}, correlating with 2N DNA and low levels of RNA) and non-G₀ (Pyronin Y^{high}, correlating with 2N–4N DNA and higher levels of RNA) populations was first delineated based on Lin[−]CD34⁺ population from the same samples (*SI Appendix, Fig. S3B*), and identical gates were used to identify G₀ and non-G₀ subsets within the HSC population (*SI Appendix, Fig. S3A*).

Cells were analyzed and sorted using a FACSAria II cytometer (BD Biosciences). A total of 50–300 HSC were sorted for in vitro assays, 500–2,000 HSC were sorted for in vivo assays, and ~1,000–10,000 HSC were sorted for RNA purification. Analysis of flow cytometry data were performed using FlowJo Software (Treestar).

In Vitro Assays: Methylcellulose and AC6.2.1 Coculture. Methylcellulose colony formation was assayed by sorting 300 cells into individual wells of a six-well plate, each containing 3 mL of complete methylcellulose (Methocult GF+

H4435; Stemcell Technologies). Plates were incubated for 12–14 d at 37 °C, and colonies then scored based on morphology.

To analyze the myeloid and B-cell lymphoid potential of HSC (20, 21, 24), 50–200 HSC were sorted into individual wells of a 96-well plate containing semiconfluent AC6.2.1 stromal cells (42) in Iscove's modified Dulbecco's medium, GlutaMAX, penicillin/streptomycin, nonessential amino acids, and sodium pyruvate. Plates were incubated for 14 d at 37 °C in 5% oxygen, and cells then analyzed by flow cytometry.

Mouse Transplantation. NSG mice obtained originally from the Jackson Laboratory were bred in a specific pathogen-free environment according to a protocol approved by the Stanford Administrative Panel on Laboratory Animal Care. P0–P2 newborn pups were preconditioned with 100 rads of γ -irradiation up to 24 h before transplantation (33, 43). A total of 500–2,000 FACS-purified HSC were resuspended in PBS containing 2% FCS and transplanted i.v. via the anterior facial vein using a 30- or 31-gauge needle.

Statistical Analysis. Student *t* test was performed using Excel (Microsoft).

RNA Purification, Amplification, and Microarray Analysis. Total RNA was extracted using TRIzol (Invitrogen) or Ambion RNA Isolation Kit (Applied Biosystems by Life Technologies) according to the manufacturer's protocols and treated with DNase I (Qiagen). All RNA samples were quantified with the RiboGreen RNA Quantitation Kit (Molecular Probes), subjected to reverse transcription, two consecutive rounds of linear amplification, and production and fragmentation of biotinylated cRNA (Affymetrix). Fifteen micrograms of cRNA from each sample was hybridized to Affymetrix HG

U133 Plus 2.0 microarrays. Hybridization and scanning were performed according to the manufacturer's instructions (Affymetrix). Raw data from all samples are available from the Gene Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo (accession no. GSE32719).

Raw data were normalized using the standard robust multichip average algorithm, together with 21,701 Affymetrix U133 Plus 2.0 human microarrays downloaded from GEO, according to methods previously described (44). Probe sets were identified to be present, and their associated transcripts expressed in elderly or young HSC if the mean of the normalized values of the probe sets of either group was greater than the threshold value calculated using the StepMiner algorithm, as previously described (45). The normalized data from probe sets that were determined to be present were then used in SAM (35) and Ingenuity Pathways Analysis (Ingenuity Systems). The categorization of genes into lymphoid and myeloid groupings was done based on evaluation of relevant literature as well as available gene expression profiling data of human and mouse lymphoid and myeloid progenitors and their differentiated progeny. Heat maps were generated using HeatMapView (GenePattern; Broad Institute).

ACKNOWLEDGMENTS. The authors thank Renee Mehra for administrative and logistical support; Ravi Majeti, Christopher Park, Matthew Inlay, and Charles Chan for helpful advice and discussions; Theresa Storm and Libuse Jerabek for excellent laboratory management; Ken Cheung for statistical advice; and the Stanford Functional Genomics Facility for array processing services. Support for this work was provided by the Stanford Medical Scientist Training Program (W.W.P.), a grant from the Siebel Stem Cell Institute and the Thomas and Stacey Siebel Foundation (to D.S.), and National Institute of Aging Grant R01AG029124 (to S.L.S. and I.L.W.).

- Bryder D, Rossi DJ, Weissman IL (2006) Hematopoietic stem cells: The paradigmatic tissue-specific stem cell. *Am J Pathol* 169:338–346.
- Chambers SM, et al. (2007) Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. *PLoS Biol* 5:e201.
- Kim M, Moon HB, Spangrude GJ (2003) Major age-related changes of mouse hematopoietic stem/progenitor cells. *Ann N Y Acad Sci* 996:195–208.
- Morrison SJ, Wandycz AM, Akashi K, Globerson A, Weissman IL (1996) The aging of hematopoietic stem cells. *Nat Med* 2:1011–1016.
- Pearce DJ, Anjos-Afonso F, Ridler CM, Eddoudi A, Bonnet D (2007) Age-dependent increase in side population distribution within hematopoiesis: Implications for our understanding of the mechanism of aging. *Stem Cells* 25:828–835.
- Rossi DJ, et al. (2005) Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc Natl Acad Sci USA* 102:9194–9199.
- Sudo K, Ema H, Morita Y, Nakauchi H (2000) Age-associated characteristics of murine hematopoietic stem cells. *J Exp Med* 192:1273–1280.
- Cho RH, Sieburg HB, Muller-Sieburg CE (2008) A new mechanism for the aging of hematopoietic stem cells: Aging changes the clonal composition of the stem cell compartment but not individual stem cells. *Blood* 111:5553–5561.
- Muller-Sieburg CE, Cho RH, Karlsson L, Huang JF, Sieburg HB (2004) Myeloid-biased hematopoietic stem cells have extensive self-renewal capacity but generate diminished lymphoid progeny with impaired IL-7 responsiveness. *Blood* 103:4111–4118.
- Dykstra B, et al. (2007) Long-term propagation of distinct hematopoietic differentiation programs in vivo. *Cell Stem Cell* 1:218–229.
- Beerman I, et al. (2010) Functionally distinct hematopoietic stem cells modulate hematopoietic lineage potential during aging by a mechanism of clonal expansion. *Proc Natl Acad Sci USA* 107:5465–5470.
- Challen GA, Boles NC, Chambers SM, Goodell MA (2010) Distinct hematopoietic stem cell subtypes are differentially regulated by TGF- β 1. *Cell Stem Cell* 6:265–278.
- Morita Y, Ema H, Nakauchi H (2010) Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. *J Exp Med* 207:1173–1182.
- Ogawa T, Kitagawa M, Hirokawa K (2000) Age-related changes of human bone marrow: A histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. *Mech Ageing Dev* 117(1–3):57–68.
- Linton PJ, Dorshkind K (2004) Age-related changes in lymphocyte development and function. *Nat Immunol* 5(2):133–139.
- Miller JP, Allman D (2003) The decline in B lymphopoiesis in aged mice reflects loss of very early B-lineage precursors. *J Immunol* 171:2326–2330.
- Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC (2004) Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. *Blood* 104:2263–2268.
- Lichtman MA, Rowe JM (2004) The relationship of patient age to the pathobiology of the clonal myeloid diseases. *Semin Oncol* 31(2):185–197.
- Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. *Proc Natl Acad Sci USA* 94:5320–5325.
- Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B (1992) Isolation of a candidate human hematopoietic stem-cell population. *Proc Natl Acad Sci USA* 89:2804–2808.
- Peault B, Weissman IL, Buckle AM, Tsukamoto A, Baum C (1993) Thy-1-expressing CD34+ human cells express multiple hematopoietic potentialities in vitro and in SCID-hu mice. *Nouv Rev Fr Hematol* 35(1):91–93.
- McCune JM, et al. (1988) The SCID-hu mouse: Murine model for the analysis of human hematolymphoid differentiation and function. *Science* 241:1632–1639.
- Negrin RS, et al. (2000) Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. *Biol Blood Marrow Transplant* 6:262–271.
- Murray L, et al. (1994) Analysis of human hematopoietic stem cell populations. *Blood Cells* 20:364–369, discussion 369–370.
- Lansdorp PM, Dragowska W, Mayani H (1993) Ontogeny-related changes in proliferative potential of human hematopoietic cells. *J Exp Med* 178:787–791.
- Gale RE, Fielding AK, Harrison CN, Linch DC (1997) Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. *Br J Haematol* 98:512–519.
- Marley SB, et al. (1999) Evidence for a continuous decline in haemopoietic cell function from birth: Application to evaluating bone marrow failure in children. *Br J Haematol* 106(1):162–166.
- Lipschitz DA, Mitchell CO, Thompson C (1981) The anemia of senescence. *Am J Hematol* 11(1):47–54.
- Kollman C, et al. (2001) Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. *Blood* 98:2043–2051.
- Waterstrat A, et al. (2008) *Telomeres and Telomerase in Ageing, Disease, and Cancer*, ed Rudolph KL (Springer, Berlin), pp 111–140.
- Taraldsrud E, et al. (2009) Age and stress related phenotypical changes in bone marrow CD34+ cells. *Scand J Clin Lab Invest* 69(1):79–84.
- Beerman I, Maloney WJ, Weissmann IL, Rossi DJ (2010) Stem cells and the aging hematopoietic system. *Curr Opin Immunol* 22:500–506.
- Majeti R, Park CY, Weissman IL (2007) Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. *Cell Stem Cell* 1:635–645.
- Manz MG, Miyamoto T, Akashi K, Weissman IL (2002) Prospective isolation of human clonogenic common myeloid progenitors. *Proc Natl Acad Sci USA* 99:11872–11877.
- Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci USA* 98:5116–5121.
- Chambers SM, et al. (2007) Hematopoietic fingerprints: An expression database of stem cells and their progeny. *Cell Stem Cell* 1:578–591.
- Nalapareddy K, Jiang H, Guachalla Gutierrez LM, Rudolph KL (2008) Determining the influence of telomere dysfunction and DNA damage on stem and progenitor cell aging: What markers can we use? *Exp Gerontol* 43:998–1004.
- Weissman IL (2005) Normal and neoplastic stem cells. *Novartis Found Symp* 265:35–50; discussion 50–54, 92–97.
- Lieber MR, Karanjawala ZE (2004) Ageing, repetitive genomes and DNA damage. *Nat Rev Mol Cell Biol* 5(1):69–75.
- Nijnik A, et al. (2007) DNA repair is limiting for hematopoietic stem cells during ageing. *Nature* 447:686–690.
- Rossi DJ, et al. (2007) Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging. *Cell Cycle* 6:2371–2376.
- Whitlock CA, Tidmarsh GF, Muller-Sieburg C, Weissman IL (1987) Bone marrow stromal cell lines with lymphopoietic activity express high levels of a pre-B neoplasia-associated molecule. *Cell* 48:1009–1021.
- Ishikawa F, et al. (2005) Development of functional human blood and immune systems in NOD/SCID/IL2 receptor gamma chain(null) mice. *Blood* 106:1565–1573.
- Sahoo D, et al. (2010) MiDREG: A method of mining developmentally regulated genes using Boolean implications. *Proc Natl Acad Sci USA* 107:5732–5737.
- Sahoo D, Dill DL, Gentles AJ, Tibshirani R, Plevritis SK (2008) Boolean implication networks derived from large scale, whole genome microarray datasets. *Genome Biol* 9:R157.1–R157.17.

Supplemental Data

Supplementary Table 1. Differentially expressed genes in elderly vs. young HSC.
SAM significant genes (FDR < 30%); age-up-regulated genes are in red, and age-down-regulated genes are in green.

Gene ID	Gene Name	Fold Change
242828_at	FIGN: fidgetin	12.84
239710_at	FIGN: fidgetin	9.40
228863_at	PCDH17: protocadherin 17	4.69
220518_at	ABI3BP: ABI gene family, member 3 (NESH) binding protein	4.25
1560698_a_at	LOC283392: hypothetical protein LOC283392	4.13
238964_at	FIGN: fidgetin	4.05
234074_at	---: CDNA FLJ10946 fis, clone PLACE1000005	3.97
220014_at	PRR16: proline rich 16	3.87
241470_x_at	---: Transcribed locus	3.84
227289_at	PCDH17: protocadherin 17	3.79
236193_at	HIST1H2BC /// HIST1H2BE /// HIST1H2BF /// HIST1H2BG /// HIST1H2BI: histone cluster 1, H2bg /// histone cluster 1, H2bf /// histone cluster 1, H2be /// histone cluster 1, H2bi /// histone cluster 1, H2bc	3.75
220679_s_at	CDH7: cadherin 7, type 2	3.45
243882_at	---: ---	3.37
241845_at	---: ---	3.33
1554007_at	---: CDNA clone IMAGE:5303689	3.31
1553808_a_at	NKX2-3: NK2 transcription factor related, locus 3 (Drosophila)	3.27
209369_at	ANXA3: annexin A3	3.27
223395_at	ABI3BP: ABI gene family, member 3 (NESH) binding protein	3.14
237009_at	---: ---	3.11
233611_at	---: CDNA FLJ12106 fis, clone HEMBB1002702	3.06
228195_at	MGC13057: hypothetical protein MGC13057	2.96
1554592_a_at	SLC1A6: solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6	2.96
228373_at	C16orf72: chromosome 16 open reading frame 72	2.94
219937_at	TRHDE: thyrotropin-releasing hormone degrading enzyme	2.93
230192_at	TRIM13: tripartite motif-containing 13	2.91
230836_at	ST8SIA4: ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4	2.88
231969_at	STOX2: storkhead box 2	2.87
1554593_s_at	SLC1A6: solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6	2.87
205656_at	PCDH17: protocadherin 17	2.84
244414_at	---: ---	2.82
226977_at	LOC492311: similar to bovine IgA regulatory protein	2.78
244674_at	---: Transcribed locus	2.77
1565913_at	---: Full length insert cDNA clone YR04D03	2.75
228821_at	ST6GAL2: ST6 beta-galactosamide alpha-2,6-sialyltransferase 2	2.74
1557756_a_at	C14orf145: chromosome 14 open reading frame 145	2.72
236548_at	GIPC2: GIPC PDZ domain containing family, member 2	2.72
1559401_a_at	---: CDNA clone IMAGE:5267013	2.71
236495_at	---: Transcribed locus	2.70
227874_at	EMCN: Endomucin	2.68
202431_s_at	MYC: v-myc myelocytomatosis viral oncogene homolog (avian)	2.65
237409_at	---: Transcribed locus	2.64
238937_at	ZNF420: zinc finger protein 420	2.63
225838_at	EPC2: enhancer of polycomb homolog 2 (Drosophila)	2.63
231979_at	---: CDNA FLJ13266 fis, clone OVARC1000960	2.63
203739_at	ZNF217: zinc finger protein 217	2.62
218979_at	RMI1: RMI1, RecQ mediated genome instability 1, homolog (S. cerevisiae)	2.60
1556931_at	---: Full length insert cDNA clone ZD58F06	2.59
230703_at	---: Transcribed locus	2.57
1565602_at	---: Full length insert cDNA clone YN67C05	2.56
204712_at	WIF1: WNT inhibitory factor 1	2.55
234033_at	---: Clone IMAGE:110218 mRNA sequence	2.54
206049_at	SELP: selectin P (granule membrane protein 140kDa, antigen CD62)	2.50
216456_at	---: MRNA; cDNA DKFZp761L0812 (from clone DKFZp761L0812); partial cds	2.49

209189_at	FOS: v-fos FBJ murine osteosarcoma viral oncogene homolog	2.49
208891_at	DUSP6: dual specificity phosphatase 6	2.48
243528_at	---: Transcribed locus	2.47
240574_at	---: CDNA clone IMAGE:5262677	2.47
208893_s_at	DUSP6: dual specificity phosphatase 6	2.45
220777_at	KIF13A: kinesin family member 13A	2.43
235052_at	ZNF792: zinc finger protein 792	2.40
212225_at	EIF1: eukaryotic translation initiation factor 1	2.40
231985_at	MICAL3: microtubule associated monooxygenase, calponin and LIM domain containing 3	2.39
236846_at	LOC284757: hypothetical protein LOC284757	2.39
241471_at	LOC730236: hypothetical LOC730236	2.39
1559042_at	NDUFB6: NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa	2.38
232504_at	LOC285628: hypothetical protein LOC285628	2.38
229298_at	KBTBD7: kelch repeat and BTB (POZ) domain containing 7	2.37
235811_at	---: ---	2.37
239208_s_at	C21orf57: Chromosome 21 open reading frame 57	2.36
214945_at	FAM153A /// FAM153B /// FAM153C: family with sequence similarity 153, member B /// family with sequence similarity 153, member A /// family with sequence similarity 153, member C	2.34
208792_s_at	CLU: clusterin	2.33
226360_at	ZNRF3: zinc and ring finger 3	2.32
1557472_a_at	FLJ30838: hypothetical gene supported by AL832565	2.32
228372_at	C10orf128: chromosome 10 open reading frame 128	2.32
239847_at	---: CDNA clone IMAGE:6186815	2.31
213005_s_at	KANK1: KN motif and ankyrin repeat domains 1	2.30
1563963_at	---: Transcribed locus	2.30
232912_at	GPR180: G protein-coupled receptor 180	2.30
240601_at	---: Transcribed locus	2.29
224956_at	NUFIP2: nuclear fragile X mental retardation protein interacting protein 2	2.29
237865_x_at	---: ---	2.29
227693_at	WDR20: WD repeat domain 20	2.29
238669_at	PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	2.29
243521_at	---: Transcribed locus	2.28
212286_at	ANKRD12: ankyrin repeat domain 12	2.28
212327_at	LIMCH1: LIM and calponin homology domains 1	2.27
240728_at	PLCB4: Phospholipase C, beta 4	2.25
212065_s_at	USP34: ubiquitin specific peptidase 34	2.25
204310_s_at	NPR2: natriuretic peptide receptor B/guanylate cyclase B (atrionatriuretic peptide receptor B)	2.24
213849_s_at	PPP2R2B: protein phosphatase 2 (formerly 2A), regulatory subunit B, beta isoform	2.23
210218_s_at	SP100: SP100 nuclear antigen	2.22
231747_at	CYSLTR1: cysteinyl leukotriene receptor 1	2.22
234605_at	CDC14B: CDC14 cell division cycle 14 homolog B (S. cerevisiae)	2.22
226298_at	RUNDC1: RUN domain containing 1	2.22
205128_x_at	PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	2.21
234986_at	---: Transcribed locus	2.21
240154_at	---: Transcribed locus	2.20
218534_s_at	AGGF1: angiogenic factor with G patch and FHA domains 1	2.20
236031_x_at	---: CDNA FLJ30128 fis, clone BRACE1000124	2.20
235532_at	PIGM: phosphatidylinositol glycan anchor biosynthesis, class M	2.20
235255_at	ATP6V0A2: ATPase, H+ transporting, lysosomal V0 subunit a2	2.19
204545_at	PEX6: peroxisomal biogenesis factor 6	2.19
226782_at	SLC25A30: solute carrier family 25, member 30	2.19
1563364_at	---: Homo sapiens, clone IMAGE:4272847, mRNA	2.19
242878_at	---: ---	2.18
241438_at	---: Transcribed locus	2.18
213506_at	F2RL1: coagulation factor II (thrombin) receptor-like 1	2.18
215388_s_at	CFH /// CFHR1: complement factor H /// complement factor H-related 1	2.17
215813_s_at	PTGS1: prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	2.17
204720_s_at	DNAJC6: DnaJ (Hsp40) homolog, subfamily C, member 6	2.17
1560697_at	LOC283392: hypothetical protein LOC283392	2.16
226189_at	ITGB8: integrin, beta 8	2.16
227404_s_at	EGR1: Early growth response 1	2.15
219738_s_at	PCDH9: protocadherin 9	2.14
236160_at	---: Transcribed locus	2.13

242579_at	BMPR1B: bone morphogenetic protein receptor, type IB	2.13
219615_s_at	KCNK5: potassium channel, subfamily K, member 5	2.13
210377_at	ACSM3: acyl-CoA synthetase medium-chain family member 3	2.12
239449_at	---: Transcribed locus	2.12
226109_at	C21orf91: chromosome 21 open reading frame 91	2.12
204071_s_at	TOPORS: topoisomerase I binding, arginine/serine-rich	2.12
223263_s_at	FGFR10P2: FGFR1 oncogene partner 2	2.11
219737_s_at	PCDH9: protocadherin 9	2.11
226483_at	TMEM68: transmembrane protein 68	2.10
220577_at	GVIN1: GTPase, very large interferon inducible 1	2.09
218294_s_at	NUP50: nucleoporin 50kDa	2.09
205942_s_at	ACSM3: acyl-CoA synthetase medium-chain family member 3	2.09
221524_s_at	RRAGD: Ras-related GTP binding D	2.09
239901_at	---: Transcribed locus	2.08
240777_at	SYNE2: Spectrin repeat containing, nuclear envelope 2	2.07
1554665_at	ZNF586: zinc finger protein 586	2.07
235342_at	SPOCK3: sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 3	2.07
237590_at	---: ---	2.06
238744_at	---: Transcribed locus	2.06
232150_at	---: CDNA clone IMAGE:4792085	2.06
227506_at	SLC16A9: solute carrier family 16, member 9 (monocarboxylic acid transporter 9)	2.06
220235_s_at	C1orf103: chromosome 1 open reading frame 103	2.06
219504_s_at	RPAP2: RNA polymerase II associated protein 2	2.05
205140_at	FPGT: fucose-1-phosphate guanylyltransferase	2.05
241399_at	FAM19A2: family with sequence similarity 19 (chemokine (C-C motif)-like), member A2	2.05
239466_at	LOC344595: hypothetical LOC344595	2.04
234326_at	---: CDNA: FLJ21248 fis, clone COL01235	2.04
1554806_a_at	FBXO8: F-box protein 8	2.04
240247_at	---: ---	2.03
203869_at	USP46: ubiquitin specific peptidase 46	2.02
1562648_at	CCDC88A: Coiled-coil domain containing 88A	2.01
1562406_at	---: CDNA clone IMAGE:5278001	2.01
217536_x_at	---: Transcribed locus	2.01
230411_at	---: CDNA FLJ41934 fis, clone PERIC2005111	2.01
209795_at	CD69: CD69 molecule	2.01
206118_at	STAT4: signal transducer and activator of transcription 4	2.00
1552735_at	PCDHGA4: protocadherin gamma subfamily A, 4	1.99
238170_at	---: Transcribed locus	1.99
239429_at	---: Transcribed locus	1.98
220572_at	DKFZp547G183: hypothetical protein DKFZp547G183	1.98
232301_at	UBE3B: ubiquitin protein ligase E3B	1.98
214713_at	YLP1: YLP motif containing 1	1.98
204739_at	CENPC1: centromere protein C 1	1.97
235264_at	HCFC2: host cell factor C2	1.97
235044_at	CYYR1: cysteine/tyrosine-rich 1	1.96
222156_x_at	CCPG1: cell cycle progression 1	1.96
230881_at	CCDC42: coiled-coil domain containing 42	1.96
204700_x_at	C1orf107: chromosome 1 open reading frame 107	1.95
243331_at	---: Transcribed locus	1.95
209006_s_at	C1orf63: chromosome 1 open reading frame 63	1.95
218614_at	C12orf35: chromosome 12 open reading frame 35	1.94
205159_at	CSF2RB: colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage)	1.94
226998_at	NARG1: NMDA receptor regulated 1	1.94
212979_s_at	FAM115A: family with sequence similarity 115, member A	1.94
209757_s_at	MYCN: v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)	1.93
243319_at	---: Transcribed locus	1.93
206861_s_at	CGGBP1: CGG triplet repeat binding protein 1	1.92
218929_at	CDKN2AIP: CDKN2A interacting protein	1.91
238609_at	C7orf38: chromosome 7 open reading frame 38	1.91
1569345_at	---: Transcribed locus	1.91
218472_s_at	PELO: pelota homolog (Drosophila)	1.90
227980_at	ZNF322A: zinc finger protein 322A	1.90
234081_at	---: CDNA FLJ11986 fis, clone HEMBB1001364	1.88

1559485_at	ATG2B: ATG2 autophagy related 2 homolog B (S. cerevisiae)	1.88
235014_at	LOC147727: hypothetical LOC147727	1.88
206109_at	FUT1: fucosyltransferase 1 (galactoside 2-alpha-L-fucosyltransferase, H blood group)	1.88
242565_x_at	C21orf57: Chromosome 21 open reading frame 57	1.88
209585_s_at	MINPP1: multiple inositol polyphosphate histidine phosphatase, 1	1.87
201143_s_at	EIF2S1: eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa	1.87
218604_at	LEMD3: LEM domain containing 3	1.85
1564175_at	LOC401074: Hypothetical LOC401074	1.85
218520_at	TBK1: TANK-binding kinase 1	1.85
226956_at	MTMR3: myotubularin related protein 3	1.84
234597_at	---: CDNA: FLJ20914 fis, clone ADSE00646	1.84
223215_s_at	C14orf100: chromosome 14 open reading frame 100	1.84
225236_at	RBM18: RNA binding motif protein 18	1.82
207128_s_at	ZNF223: zinc finger protein 223	1.81
227559_at	---: Transcribed locus	1.81
229373_at	---: Transcribed locus	1.79
238725_at	---: Transcribed locus	1.79
227410_at	FAM43A: family with sequence similarity 43, member A	1.79
241116_at	---: Transcribed locus	1.79
1560274_at	LOC100132279 /// WTAP: Wilms tumor 1 associated protein /// hypothetical protein LOC100132279	1.79
1555486_a_at	FLJ14213: protor-2	1.79
1554501_at	TSC22D4: TSC22 domain family, member 4	1.79
239081_at	---: Transcribed locus	1.78
201694_s_at	EGR1: early growth response 1	1.78
218535_s_at	RIOK2: RIO kinase 2 (yeast)	1.77
204447_at	ProSAPiP1: ProSAPiP1 protein	1.76
224628_at	C2orf30: chromosome 2 open reading frame 30	1.76
236360_at	FLJ42875: hypothetical LOC440556	1.76
206016_at	CCDC22: coiled-coil domain containing 22	1.76
215525_at	---: ---	1.75
219383_at	FLJ14213: protor-2	1.75
202097_at	NUP153: nucleoporin 153kDa	1.75
228753_at	LOC100128737: hypothetical protein LOC100128737	1.74
213109_at	TNIK: TRAF2 and NCK interacting kinase	1.74
238355_at	RBM39: RNA binding motif protein 39	1.74
222893_s_at	RPAP2: RNA polymerase II associated protein 2	1.73
219436_s_at	EMCN: endomucin	1.73
213376_at	ZBTB1: zinc finger and BTB domain containing 1	1.72
233226_at	PTPN9: Protein tyrosine phosphatase, non-receptor type 9	1.71
203761_at	SLA: Src-like-adaptor	1.71
225132_at	FBXL3: F-box and leucine-rich repeat protein 3	1.71
226280_at	---: CDNA FLJ43545 fis, clone PROST2011631	1.70
244613_at	---: ---	1.69
209193_at	PIM1: pim-1 oncogene	1.69
236128_at	ZNF91: zinc finger protein 91	1.67
216465_at	---: MRNA; cDNA DKFZp586N2022 (from clone DKFZp586N2022)	1.67
223470_at	PIGM: phosphatidylinositol glycan anchor biosynthesis, class M	1.67
205928_at	ZNF443: zinc finger protein 443	1.66
221025_x_at	PUS7L: pseudouridylate synthase 7 homolog (S. cerevisiae)-like	1.65
201236_s_at	BTG2: BTG family, member 2	1.64
232265_at	ATXN7L1: ataxin 7-like 1	1.64
225005_at	PHF13: PHD finger protein 13	1.62
225445_at	tcag7.1228: hypothetical protein FLJ25778	1.61
222312_s_at	---: CDNA clone IMAGE:6186815	1.61
200881_s_at	DNAJA1: DnaJ (Hsp40) homolog, subfamily A, member 1	1.61
213233_s_at	KLHL9: kelch-like 9 (Drosophila)	1.60
241445_at	---: Transcribed locus	1.59
214651_s_at	HOXA9: homeobox A9	1.57
227066_at	MOBK12C: MOB1, Mps One Binder kinase activator-like 2C (yeast)	1.56
230520_at	AIG1: androgen-induced 1	1.56
238279_x_at	---: ---	1.55
1569098_s_at	TP53BP1: tumor protein p53 binding protein 1	1.55
225490_at	ARID2: AT rich interactive domain 2 (ARID, RFX-like)	1.54

223377_x_at	CISH: cytokine inducible SH2-containing protein	1.54
242761_s_at	ZNF420: zinc finger protein 420	1.52
201041_s_at	DUSP1: dual specificity phosphatase 1	1.51
228445_at	AIFM2: apoptosis-inducing factor, mitochondrion-associated, 2	1.50
218079_s_at	GGNBP2: gametogenetin binding protein 2	1.50
226504_at	FAM109B: family with sequence similarity 109, member B	1.48
225121_at	TBC1D23: TBC1 domain family, member 23	1.48
225912_at	TP53INP1: tumor protein p53 inducible nuclear protein 1	-1.70
226419_s_at	FLJ44342: hypothetical LOC645460	-1.73
206674_at	FLT3: fms-related tyrosine kinase 3	-1.76
224606_at	KLF6: Kruppel-like factor 6	-1.78
241353_s_at	LOC100129105: similar to hCG1821214	-1.86
225673_at	MYADM: myeloid-associated differentiation marker	-1.93
204639_at	ADA: adenosine deaminase	-1.98
208763_s_at	TSC22D3: TSC22 domain family, member 3	-2.03
244080_at	---: Transcribed locus, strongly similar to XP_001151823.1 PREDICTED: hypothetical protein [Pan troglodytes]	-2.04
36829_at	PER1: period homolog 1 (Drosophila)	-2.07
214176_s_at	---: Transcribed locus	-2.11
226525_at	---: Transcribed locus	-2.17
215671_at	PDE4B: phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)	-2.34
230986_at	KLF8: Kruppel-like factor 8	-2.36
213665_at	SOX4: SRY (sex determining region Y)-box 4	-2.39
236253_at	---: Transcribed locus	-2.49
229178_at	LOC145786: hypothetical protein LOC145786	-2.56
223708_at	C1QTNF4: C1q and tumor necrosis factor related protein 4	-2.64
228983_at	---: Transcribed locus	-2.78
231508_s_at	---: Transcribed locus	-2.79
214043_at	PTPRD: protein tyrosine phosphatase, receptor type, D	-2.80
201324_at	EMP1: epithelial membrane protein 1	-2.81
207735_at	RNF125: ring finger protein 125	-2.82
1552803_a_at	C1orf215: chromosome 1 open reading frame 215	-2.82
202861_at	PER1: period homolog 1 (Drosophila)	-2.96
222044_at	PCIF1: PDX1 C-terminal inhibiting factor 1	-2.96
204784_s_at	MLF1: myeloid leukemia factor 1	-3.03
228188_at	FOSL2: FOS-like antigen 2	-3.15
230233_at	---: Transcribed locus	-3.21
242051_at	---: Transcribed locus	-3.22
239476_at	---: CDNA FLJ36491 fis, clone THYMU2018197	-3.26
1561079_at	ANKRD28: ankyrin repeat domain 28	-3.29
206726_at	PGDS: prostaglandin D2 synthase, hematopoietic	-3.50
203708_at	PDE4B: phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila)	-3.79
239809_at	---: Transcribed locus	-4.17
205239_at	AREG /// LOC727738: amphiregulin (schwannoma-derived growth factor) /// similar to Amphiregulin precursor (AR) (Colorectum cell-derived growth factor) (CRDGF)	-7.56
215446_s_at	LOX: lysyl oxidase	-10.59

Supplementary Table 2. Selected list of genes that have been implicated in hematopoietic malignancies and are differentially expressed between elderly and young human HSC; age-up-regulated genes are in red, and age-down-regulated genes are in green.


Gene ID	Gene Name	Fold Change
208079_s_at	AURKA: aurora kinase A	1.81
209189_at	FOS: v-fos FBJ murine osteosarcoma viral oncogene homolog	2.49
209905_at	HOXA9: homeobox A9	1.62
202431_s_at	MYC: v-myc myelocytomatosis viral oncogene homolog (avian)	2.65
230192_at	TRIM13: tripartite motif-containing 13	2.91
36711_at	MAFF: v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)	-2.06
206674_at	FLT3: fms-related tyrosine kinase 3	-1.76

Supplementary Table 3. Complete blood count (CBC) values from matching peripheral blood of bone marrow samples used for this study (data available for subset of samples only).

		Complete Blood Count						
Age	Gender	WBC	Hb	HCT	PLT	MCV	RDW	RBC
24	Male	5.3	14.1	39.8	225	87.2	13.1	4.57
24	Female	8.5	13.1	37.6	269	93.7	12.5	4.01
26	Female	4.5	14	14.3	198	94.6	13.7	4.36
26	Male	4.3	14.4	41.8	200	89.5	13.5	4.67
27	Female	7.3	15.9	45.4	224	87.7	12.9	5.18
30	Female	6.3	13.1	37.8	191	89.3	13.6	4.23
31	Male	8.1	14.4	40.8	274	93.8	14.4	4.35
65	Male	5.2	14.6	43	195	91	13.9	4.72
65	Male	4.7	15.1	43.6	184	91	14.1	4.78
68	Male	7	14.8	42.8	236	92	13.1	4.68
68	Male	8.1	13.2	38.4	230	98	12.1	3.92
73	Male	5.6	13.4	38.4	295	87	13.1	4.41
75	Male	7.3	15.1	44	219	89.5	13.8	4.91
81	Male	9.4	15.4	44.9	188	89.5	14.7	5.02
83	Female	7.1	13.3	39.4	250	89.9	14.1	4.38
85	Female	5.1	12.7	37	215	100.5	13.7	3.68
85	Female	6.2	13.8	41.1	163	87.4	15.3	4.7

Supplementary Figure 1. Increased frequency of HSC out of total mononuclear cells isolated from normal elderly bone marrow compared to young.




(A) Summary of HSC as frequency of total bone marrow mononuclear cell population from multiple young (n=13) and elderly (n=11) bone marrow samples. * = $p < 0.002$. (B) CD34+ cells as frequency of total bone marrow mononuclear cell population from multiple young (n=13) and elderly (n=11) bone marrow samples. (C) Relative HSC as frequency of total bone marrow mononuclear cell population from multiple young (n=13) and elderly (n=11) bone marrow samples, adjusted for bone marrow cellularity, as estimated from bone marrow core biopsies. # = $p < 0.02$. Error bars represent standard deviation.



Supplementary Figure 1

Supplementary Figure 2. Frequency of MPP in normal elderly bone marrow compared to young.

(A) Gating strategy and flow cytometric profile of MPP (Lin^- , CD34^+ , CD38^- , CD90^- , CD45RA^-) in representative hematopoietically normal young (left) and elderly (right) bone marrow samples. The panels for each sample are gated on $\text{Lin-CD34}^+\text{CD38}^-$ live cells. (B) Summary of MPP as frequency of total $\text{Lin}^- \text{CD34}^+$ population from multiple young ($n=13$) and elderly ($n=11$) bone marrow samples. (C) Summary of MPP as frequency of total bone marrow mononuclear cell population from multiple young ($n=13$) and elderly ($n=11$) bone marrow samples. Error bars represent standard deviation.




Supplementary Figure 2


Supplementary Figure 3. Gating strategy and cell cycle flow cytometric profile of live, Lin⁻ CD34⁺ cells.

(A) Gating strategy and flow cytometric profile of quiescent G₀ (Hoechst 33342^{low}, Pyronin Y^{low}, correlating with 2N DNA and low levels of RNA) and non-G₀ (Pyronin Y^{high}, correlating with 2N to 4N DNA and higher levels of RNA) populations in representative elderly and young HSC from hematopoietically normal bone marrow samples. The panels for each sample are gated on Lin-CD34⁺CD38⁻CD90⁺CD45RA⁻ live cells. (B) Quiescent G₀ (Hoechst 33342^{low}, Pyronin Y^{low}, correlating with 2N DNA and low levels of RNA) and non-G₀ (Pyronin Y^{high}, correlating with 2N to 4N DNA and higher levels of RNA) populations in representative elderly and young Lin⁻ CD34⁺ population from hematopoietically normal bone marrow samples. The panel is gated on Lin-CD34⁺CD38⁻CD90⁺CD45RA⁻ live cells. This profile was used to set gates for Hoechst 33342 and Pyronin Y in (A).


A Young Bone Marrow (31 year old, male):
Live, Lin-CD34+CD38-CD90+:



Elderly Bone Marrow (83 year old, female):
Live, Lin-CD34+CD38-CD90+:




B Live, Lin-CD34+:



Supplementary Figure 4. Similar myeloid progenitor frequencies in normal elderly and young bone marrow.



(A) Gating strategy and flow cytometric profile of CMP ($\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD123}^+ \text{CD45RA}^-$), GMP ($\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD123}^+ \text{CD45RA}^+$), and MEP ($\text{Lin}^- \text{CD34}^+ \text{CD38}^+ \text{CD123}^- \text{CD45RA}^-$) in representative hematopoietically normal young and elderly bone marrow samples. The left panels for each sample are gated on lineage negative (Lin^-) live cells, and the right panels are gated on $\text{Lin}^- \text{CD34}^+ \text{CD38}^+$ live cells. (B) Summary of myeloid progenitor (CMP, GMP, and MEP) frequencies as total of $\text{Lin}^- \text{CD34}^+$ population from multiple young ($n=13$) and elderly ($n=11$) bone marrow samples. (B) Summary of myeloid progenitor (CMP, GMP, and MEP) frequencies as total of bone marrow mononuclear cell population from multiple young ($n=13$) and elderly ($n=11$) bone marrow samples. Error bars represent standard deviation.



Supplementary Figure 4

Supplementary Figure 5. Decreased frequency of CLP out of total mononuclear cells isolated from normal elderly bone marrow compared to young.

Summary of CLP as frequency of total bone marrow mononuclear cell population from multiple young (n=10) and elderly (n=7) bone marrow samples. # = $p < 0.05$. Error bars represent standard deviation.




Supplementary Figure 5


Supplementary Figure 6. Generation of lymphoid and myeloid progeny *in vitro* by HSC from normal young and elderly bone marrow.

(A) Summary of numbers and types of cells produced per 50 HSC from multiple normal young (n=8) and elderly (n=6) bone marrow samples co-cultured with AC6.2.1 stromal cell line. (B) Summary of numbers and types of colonies produced by 300 HSC from multiple normal young (n=6) and elderly (n=6) bone marrow samples cultured in methylcellulose medium. Error bars represent standard deviation.

A






B



Supplementary Figure 7. Engraftment of human T cells, erythroid cells, and platelets

(A) Summary of spleen engraftment of human CD45+CD3+ T cells as measured by percent human chimerism per 500 transplanted HSC from unique young (n=10) and elderly (n=9) bone marrow samples. (B) Summary of bone marrow engraftment of human glycophorin A+ erythroid cells. (C) Summary of bone marrow engraftment of human CD41/61+ platelets. Error bars represent standard deviation.




Supplementary Figure 7


Supplementary Figure 8. Purification of HSC from bone marrow by FACS

(A) Representative flow cytometric profile of HSC prior to sorting. (B) Representative flow cytometric profile of sorted HSC which were re-analyzed to assess purity. (C) Summary of sort purity of sorted HSC from multiple young (n=11) and elderly (n=8) bone marrow samples.

A Pre-sort:
Live, Lin⁻, CD34⁺,CD38⁻:



B Post-sort:
Live:




C

Samples	Post-sort purity (range)
Elderly HSC (8 samples)	96.55%-100.00%
Young HSC (11 samples)	95.25%-100.00%

Supplementary Figure 9. Ingenuity Pathways Analysis of age-regulated genes.

(A) The “Cell Cycle, Connective Tissue Development and Function, Cellular Development” network and (B) the “Gene Expression, Hematological System Development and Function, Tissue Morphology” network are identified by IPA, based on the age-regulated genes from SAM, as the most significantly affected during human HSC aging. Selection of (B) biological functions and (C) molecular pathways identified by IPA as significantly enriched in the age-regulated HSC geneset.



Supplementary Figure 9